Lars Steinbrück

Title: Lars Steinbrück: Innovator in Immune Suppression

Introduction

Lars Steinbrück is a notable inventor based in Hannover, Germany. He has made significant contributions to the field of immunology through his innovative research and patenting efforts. His work focuses on developing new binder molecules that can alter immune responses, which has important implications for medical treatments.

Latest Patents

Lars Steinbrück holds a patent for an "Immune suppressor and its use." This invention relates to a new binder molecule that serves as an immune suppressor. The UL11 protein of human cytomegalovirus has been identified as a key component that binds to the CD45 molecule, potentially altering an individual's immune system. The patent also covers binder molecules, particularly fusion molecules that combine the CD45 binding domain of the UL11 protein with a second molecule of interest for targeted delivery to cells expressing the CD45 molecule. Additionally, the invention includes pharmaceutical compositions comprising the UL11 protein or its derivatives, as well as nucleic acid sequences encoding the same.

Career Highlights

Lars Steinbrück is affiliated with the Medical University of Hannover, where he conducts his research and development activities. His work has led to advancements in understanding immune suppression and the potential therapeutic applications of his inventions.

Collaborations

Lars collaborates with esteemed colleagues, including Penelope Kay-Fedorov and Martin Messerle. Their combined expertise enhances the research and development efforts in the field of immunology.

Conclusion

Lars Steinbrück is a pioneering inventor whose work on immune suppressors has the potential to transform medical treatments. His innovative approach and collaboration with other experts in the field underscore the importance of research in advancing healthcare solutions.